NASDAQ:HROWM - Nasdaq - US4158583074 - Currency: USD
HARROW INC - HROW 11 7/8 12/31/27
NASDAQ:HROWM (5/16/2025, 8:00:01 PM)
26.235
-0.46 (-1.74%)
The current stock price of HROWM is 26.235 USD. In the past month the price decreased by -0.4%. In the past year, price decreased by -0.1%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 55.04 | 718.00B | ||
JNJ | JOHNSON & JOHNSON | 15.06 | 364.11B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 18.6 | 285.74B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.19 | 216.45B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 18.5 | 213.34B | ||
MRK | MERCK & CO. INC. | 9.76 | 191.40B | ||
PFE | PFIZER INC | 7.11 | 129.48B | ||
SNY | SANOFI-ADR | 13.64 | 126.52B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 6.37 | 95.14B | ||
GSK | GSK PLC-SPON ADR | 6.91 | 76.16B | ||
ZTS | ZOETIS INC | 27.08 | 72.73B | ||
HLN | HALEON PLC-ADR | 22.5 | 48.70B |
Harrow, Inc. engages in the development, production, and sale of innovative medications. The company is headquartered in Nashville, Tennessee and currently employs 382 full-time employees. The company went IPO on 2013-02-08. The firm is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. The company provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. The company owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. The company owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. The company owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
HARROW INC - HROW 11 7/8 12/31/27
1A Burton Hills Blvd, Suite 200
Nashville TENNESSEE US
Employees: 382
Phone: 16157334731
The current stock price of HROWM is 26.235 USD. The price decreased by -1.74% in the last trading session.
The exchange symbol of HARROW INC - HROW 11 7/8 12/31/27 is HROWM and it is listed on the Nasdaq exchange.
HROWM stock is listed on the Nasdaq exchange.
11 analysts have analysed HROWM and the average price target is 63.12 USD. This implies a price increase of 140.61% is expected in the next year compared to the current price of 26.235. Check the HARROW INC - HROW 11 7/8 12/31/27 stock analysts ratings, price target forecast and up-and down grades for more detailed information.
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) has a market capitalization of 962.56M USD. This makes HROWM a Small Cap stock.
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) currently has 382 employees.
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) has a support level at 26.13 and a resistance level at 26.3. Check the full technical report for a detailed analysis of HROWM support and resistance levels.
The Revenue of HARROW INC - HROW 11 7/8 12/31/27 (HROWM) is expected to grow by 45.22% in the next year. Check the estimates tab for more information on the HROWM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) has a dividend yield of 11.12%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of HROWM dividend history, reliability and sustainability.
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) will report earnings on 2025-08-05, after the market close.
HARROW INC - HROW 11 7/8 12/31/27 (HROWM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.56).
The outstanding short interest for HARROW INC - HROW 11 7/8 12/31/27 (HROWM) is 0% of its float. Check the ownership tab for more information on the HROWM short interest.
ChartMill assigns a technical rating of 2 / 10 to HROWM. When comparing the yearly performance of all stocks, HROWM turns out to be only a medium performer in the overall market: it outperformed 50.59% of all stocks.
ChartMill assigns a fundamental rating of 5 / 10 to HROWM. While HROWM is still in line with the averages on profitability rating, there are concerns on its financial health.
Over the last trailing twelve months HROWM reported a non-GAAP Earnings per Share(EPS) of -0.56. The EPS increased by 37.78% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -4.49% | ||
ROE | -25.1% | ||
Debt/Equity | 3.15 |
ChartMill assigns a Buy % Consensus number of 84% to HROWM. The Buy consensus is the average rating of analysts ratings from 11 analysts.
For the next year, analysts expect an EPS growth of 213.59% and a revenue growth 45.22% for HROWM